Navigation Links
EnVivo Pharmaceuticals Announces Executive Appointment
Date:9/26/2007

Dr. Dana C. Hilt Named SVP, Clinical Development & Chief Medical Officer

WATERTOWN, Mass., Sept. 26 /PRNewswire/ -- EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced the appointment of Dr. Dana C. Hilt as Senior Vice President and Chief Medical Officer. He will be responsible for coordinating all pre-clinical and clinical development activities of EnVivo's growing pipeline.

Dr. Hilt, 55, previously served as Senior Vice President, Clinical Research and Medical Affairs & Chief Medical Officer for Critical Therapeutics in Lexington, Massachusetts. Dr. Hilt is a distinguished neurologist with extensive drug development experience from his tenures at Amgen, Guilford Pharmaceuticals and Ascend Therapeutics. In addition, he has held both scientific and professorial positions with the University of Southern California School of Medicine, the National Institutes of Health and the University of Maryland School of Medicine where he was a clinical Associate Professor in the department of Neurology. At the beginning of his career, he was a Resident Fellow in Neurology at the Johns Hopkins University School of Medicine and interned at Harvard University Medical School.

Dr. Hilt is a member of the American Academy of Neurology, Movement Disorders Society, American Society for Experimental Neurotherapeutics, American Association for the Advancement of Science, Society for Neuroscience and Endocrine Society. He is the author of over 50 publications. Dr. Hilt received his Bachelor of Science Degree in Chemistry (with Distinction) from the University of Maine and an M.D. from the Tufts University School of Medicine.

"Given the continuing growth of EnVivo's pre-clinical and clinical programs in the field of neuro-degenerative diseases, Dana brings critically important skills to the management team. His deep expertise in drug development will be of increasing importance as we progress our pipeline and are seeking to further broaden our pipeline in the next two years," said Kees Been, President and Chief Executive Officer.

EnVivo Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders including, Alzheimer's disease, Parkinson's disease, Huntington's disease and Spino Cerebellar Ataxias. The company's lead programs include a Nicotinic Acetylcholine Receptor Agonist Program (alpha-7) for Alzheimer's disease and Schizophrenia, a Histone Deacetylase (HDAC) program for Huntington's disease, EVP2442 program for neuron-protection and the PDE10 inhibitor and gamma- secretase modulator programs. For more information see http://www.envivopharma.com


'/>"/>
SOURCE EnVivo Pharmaceuticals, Inc.,
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial ... microbiome impact grant award has been made to Dr. Renato Polimanti of Yale ... drinking on the oral microbiome. Grant proposals have been vetted by the company’s ...
(Date:12/2/2016)... Dec. 2, 2016 More than $4.3 million was ... Medals dinner ( DHMD ). The gala was held at the ... York City and honored Alan Alda ... to health and medicine and the public understanding of science. ... 2006, the event has raised $40 million for the Laboratory,s ...
(Date:12/2/2016)... , Dec 2, 2016 Research and ... "Nanobiotechnology Applications, Markets and Companies" to their offering. ... , , ... by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will ... formulations for optimal delivery to diagnostic applications in clinical trials. ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... Science Symposium (CSS) and the popularity of US Single Day Events (SDE) to ... in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):